Applied Clinical Trials Feature: AI-Powered eCOA Localization and COA Migration

YPrime was featured in Applied Clinical Trials for its research on AI-powered eCOA localization and clinical outcome assessment (COA) migration, highlighting how artificial intelligence can reduce migration errors, accelerate clinical trial startup timelines, and support broader global patient participation.

In this Applied Clinical Trials feature, YPrime shares data from a multi-study analysis demonstrating how AI-enabled COA migration into eCOA platforms improves first-pass accuracy, shortens localization review cycles, and preserves linguistic and regulatory integrity across global trials. The findings reflect a growing industry focus on scalable eCOA localization, inspection-ready data workflows, and faster study activation without compromising quality.

This research was also presented at ISPOR, reinforcing YPrime’s leadership in applying AI responsibly to solve one of the most persistent bottlenecks in global eCOA delivery.

Why This Matters for Sponsors Running Global eCOA Trials

As clinical trials expand into more regions and languages, eCOA localization and COA migration have become critical path activities for study startup and patient access. Manual, error-prone migration processes can delay first-patient-in, increase re-proofing cycles, and introduce unnecessary risk into regulatory submissions.

YPrime’s AI-supported approach to eCOA localization demonstrates how sponsors can reduce localization delays, maintain linguistic accuracy, and scale global trials with confidence—without removing the human oversight regulators expect. By automating the most technical aspects of COA migration and preserving expert linguistic review, YPrime helps sponsors move faster while protecting data integrity and patient experience.

To explore the full dataset and learn how YPrime applies AI to eCOA localization in production environments, view the ISPOR poster.

To learn more about YPrime eCOA, visit www.yprime.com/ecoa.